Lisa Bodei

Jun 8, 2023 | jnm.snmjournals.org | Thomas A Hope |Emmanuel S. Antonarakis |Lisa Bodei |Jérémie Calais

CURRENT CLINICAL STRUGGLESPatients should be effectively castrate for the duration of PSMA RLT. Patients may also receive treatment with ARPIs such as abiraterone or enzalutamide. In the VISION trial, 53% of patients initiated ARPIs along with 177Lu-PSMA-617, and ARPIs can be safely continued during PSMA RLT treatment (14). Currently, there is no evidence for or against using ARPI with PSMA RLT.